Rapport Therapeutics (RAPP) News Today $10.05 -0.17 (-1.66%) As of 03/25/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Vanda Pharmaceuticals (NASDAQ:VNDA) & Rapport Therapeutics (NASDAQ:RAPP) Head-To-Head AnalysisMarch 25 at 1:37 AM | americanbankingnews.comRapport Therapeutics to present data at 2025 AAN meetingMarch 22, 2025 | markets.businessinsider.comBpce: Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCEMarch 21, 2025 | globenewswire.comRapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual MeetingMarch 21, 2025 | globenewswire.comPositive Signs As Multiple Insiders Buy Rapport Therapeutics StockMarch 15, 2025 | finance.yahoo.comInsider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of SharesMarch 15, 2025 | finance.yahoo.comWendy B. Young Buys 6,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockRapport Therapeutics (NASDAQ:RAPP - Get Free Report) Director Wendy B. Young acquired 6,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were acquired at an average price of $10.21 per share, for a total transaction of $61,260.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at $61,260. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.March 14, 2025 | marketbeat.comInsider Buying: Rapport Therapeutics (NASDAQ:RAPP) CFO Purchases 9,900 Shares of StockRapport Therapeutics (NASDAQ:RAPP - Get Free Report) CFO Troy A. Ignelzi acquired 9,900 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was purchased at an average cost of $10.10 per share, for a total transaction of $99,990.00. Following the completion of the purchase, the chief financial officer now directly owns 9,900 shares of the company's stock, valued at $99,990. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.March 14, 2025 | marketbeat.comWendy B. Young Buys 6,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockMarch 14, 2025 | insidertrades.comCorrection: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024March 13, 2025 | globenewswire.comCorrection: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024March 13, 2025 | globenewswire.comRapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 13, 2025 | finanznachrichten.deMise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024March 13, 2025 | globenewswire.comRapport Therapeutics sees cash runway through 2026March 12, 2025 | markets.businessinsider.comRapport Therapeutics Reports 2024 Financial Results and ProgressMarch 12, 2025 | tipranks.comRapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last yearMarch 11, 2025 | markets.businessinsider.comRapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 11, 2025 | gurufocus.comRapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 11, 2025 | globenewswire.comRapport Therapeutics Inc trading resumesMarch 4, 2025 | markets.businessinsider.comRapport Therapeutics Inc trading halted, volatility trading pauseMarch 4, 2025 | markets.businessinsider.comRapport Therapeutics Appoints New CMO Amid Phase 2a UpdatesMarch 3, 2025 | tipranks.comRapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine DevelopmentMarch 3, 2025 | globenewswire.comRapport Therapeutics to Participate in Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comRapport Therapeutics (RAPP) Expected to Announce Earnings on ThursdayRapport Therapeutics (NASDAQ:RAPP) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 22, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 8.5% - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5% - Here's WhyFebruary 19, 2025 | marketbeat.comRapport Therapeutics, Inc. (RAPP)February 15, 2025 | ca.finance.yahoo.comRapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel NicolausFebruary 11, 2025 | markets.businessinsider.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Time to Buy?Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Time to Buy?February 10, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.6% - Should You Sell?Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.6% - Here's What HappenedFebruary 7, 2025 | marketbeat.comJennison Associates LLC Invests $1.11 Million in Rapport Therapeutics (NASDAQ:RAPP)Jennison Associates LLC bought a new position in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 62,287 shares of the company's stock, valued at approximFebruary 7, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Short Interest UpdateRapport Therapeutics (NASDAQ:RAPP - Get Free Report) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 1,500,000 shares, a decline of 15.3% from the December 31st total of 1,770,000 shares. Currently, 8.6% of the company's stock are short sold. Based on an average daily volume of 104,700 shares, the days-to-cover ratio is presently 14.3 days.February 1, 2025 | marketbeat.comRapport Therapeutics (RAPP) Projected to Post Quarterly Earnings on ThursdayRapport Therapeutics (NASDAQ:RAPP) will be releasing earnings on Thursday, February 6, Financial Modeling Prep reports.January 30, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading 4.6% Higher - Still a Buy?Rapport Therapeutics (NASDAQ:RAPP) Shares Up 4.6% - Here's WhyJanuary 29, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Here's WhyRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up - Still a Buy?January 15, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month Low - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month Low - Time to Sell?January 14, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - Here's WhyJanuary 13, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Down 6.9% - What's Next?Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9% - What's Next?January 10, 2025 | marketbeat.comRapport Therapeutics’ Promising Trial Results and Leadership ChangeJanuary 10, 2025 | tipranks.comCORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS DisordersJanuary 9, 2025 | globenewswire.comRapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS DisordersJanuary 9, 2025 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Sets New 52-Week Low - Here's What HappenedRapport Therapeutics (NASDAQ:RAPP) Reaches New 52-Week Low - What's Next?January 8, 2025 | marketbeat.comGeode Capital Management LLC Purchases New Shares in Rapport Therapeutics (NASDAQ:RAPP)Geode Capital Management LLC purchased a new position in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 201,748 shares of the company's stock, valued at approximately $4,133,000.January 6, 2025 | marketbeat.comState Street Corp Invests $1.19 Million in Rapport Therapeutics (NASDAQ:RAPP)State Street Corp acquired a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 58,046 shares of the company's stock, valued at approximately $1,189,000. State StreeJanuary 3, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 4% - Here's WhyRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4% - Should You Sell?December 31, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 4.6% - Time to Sell?Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4.6% - What's Next?December 19, 2024 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7% - Here's What HappenedRapport Therapeutics (NASDAQ:RAPP) Trading Up 5.7% - Should You Buy?December 18, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys New Stake in Rapport Therapeutics (NASDAQ:RAPP)Charles Schwab Investment Management Inc. acquired a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 73,146 shares of the company's stock, valDecember 17, 2024 | marketbeat.comRapport Therapeutics management to meet with TruistDecember 6, 2024 | tipranks.comRapport Therapeutics presents data on long episode seizure biomarkerDecember 6, 2024 | tipranks.comRapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical SeizuresDecember 6, 2024 | globenewswire.com Remove Ads Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPP Media Mentions By Week RAPP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPP News Sentiment▼0.310.77▲Average Medical News Sentiment RAPP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPP Articles This Week▼52▲RAPP Articles Average Week Remove Ads Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANIP News Today DYN News Today INDV News Today AMPH News Today ARDX News Today EVO News Today ETNB News Today OCUL News Today GPCR News Today IOVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPP) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
